Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2529-2540

  Zhang, Guangyun ^a   Xia, Feng ^a   Zhang, Yunxia ^a,b   Zhang, Xiao ^a   Cao, Yuhong ^a   Wang, Ling ^c   Liu, Xuedong ^a   Zhao, Gang ^a   Shi, Ming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Ginsenoside Rd; Inflammation; Ischemic stroke; Microglia; Pooled analysis; Proteasome

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; GINSENOSIDE RD; GLUCOSE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GINSENOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BARTHEL INDEX; BRAIN ISCHEMIA; CELL PROLIFERATION; CELL TRANSPORT; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ENZYME PHOSPHORYLATION; GLUCOSE BLOOD LEVEL; HUMAN; IKAPPABALPHA GENE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MOUSE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RAT; SPLEEN; THYMUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL NUCLEUS; CEREBRAL ARTERY DISEASE; COMPLICATION; DRUG EFFECTS; METABOLISM; NEWBORN; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; STROKE;

ANIMALS; ANIMALS, NEWBORN; BRAIN ISCHEMIA; CELL NUCLEUS; CYTOKINES; DEXAMETHASONE; GINSENOSIDES; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFLAMMATION; MALE; MICE, INBRED C57BL; MICROGLIA; NF-KAPPA B; NF-KAPPAB INHIBITOR ALPHA; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS, SPRAGUE-DAWLEY; STROKE; TREATMENT OUTCOME;

EID: 84931037159     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9261-8     Document Type: Article

References (40)

1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V (2009) Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 8(4):355–369. doi:10.1016/S1474-4422(09)70025-0
2. Norrving B, Kissela B (2013) The global burden of stroke and need for a continuum of care. Neurology 80(3 Suppl 2):S5–S12. doi:10.1212/WNL.0b013e3182762397
3. Sahota P, Savitz SI (2011) Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 8(3):434–451. doi:10.1007/s13311-011-0040-6
4. Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW (2011) How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol 7(7):400–409. doi:10.1038/nrneurol.2011.89
5. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379(9834):2364–2372. doi:10.1016/S0140-6736(12)60738-7
6. Stroke Unit Trialists C (2007) Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 4, CD000197. doi:10.1002/14651858.CD000197.pub2
7. Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C (2012) Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 7(5):407–418. doi:10.1111/j.1747-4949.2012.00770.x
8. Wahlgren NG, Ahmed N (2004) Neuroprotection in cerebral ischaemia: facts and fancies—the need for new approaches. Cerebrovasc Dis 17(Suppl 1):153–166. doi:10.1159/000074808
9. Edaravone Acute Infarction Study G (2003) Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 15(3):222–229
10. Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM et al (2012) Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 11(11):942–950. doi:10.1016/S1474-4422(12)70225-9
11. Liu X, Wang L, Wen A, Yang J, Yan Y, Song Y, Ren H, Wu Y et al (2012) Ginsenoside-Rd improves outcome of acute ischaemic stroke—a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurol Offic J Eur Fed Neurol Soc 19(6):855–863. doi:10.1111/j.1468-1331.2011.03634.x
12. Liu X, Xia J, Wang L, Song Y, Yang J, Yan Y, Ren H, Zhao G (2009) Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial. Eur J Neurol Offic J Eur Fed Neurol Soc 16(5):569–575. doi:10.1111/j.1468-1331.2009.02534.x
13. Li L, Liu J, Yan X, Qin K, Shi M, Lin T, Zhu Y, Kang T et al (2011) Protective effects of ginsenoside Rd against okadaic acid-induced neurotoxicity in vivo and in vitro. J Ethnopharmacol 138(1):135–141. doi:10.1016/j.jep.2011.08.068
14. Ye R, Han J, Kong X, Zhao L, Cao R, Rao Z, Zhao G (2008) Protective effects of ginsenoside Rd on PC12 cells against hydrogen peroxide. Biol Pharm Bull 31(10):1923–1927
15. Ye R, Kong X, Yang Q, Zhang Y, Han J, Li P, Xiong L, Zhao G (2011) Ginsenoside rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window. Neurotherapeutics 8(3):515–525. doi:10.1007/s13311-011-0051-3
16. Ye R, Kong X, Yang Q, Zhang Y, Han J, Zhao G (2011) Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. Neuropharmacology 61(4):815–824. doi:10.1016/j.neuropharm.2011.05.029
17. Ye R, Li N, Han J, Kong X, Cao R, Rao Z, Zhao G (2009) Neuroprotective effects of ginsenoside Rd against oxygen-glucose deprivation in cultured hippocampal neurons. Neurosci Res 64(3):306–310. doi:10.1016/j.neures.2009.03.016
18. Ye R, Yang Q, Kong X, Han J, Zhang X, Zhang Y, Li P, Liu J et al (2011) Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem Int 58(3):391–398. doi:10.1016/j.neuint.2010.12.015
19. Ye R, Zhang X, Kong X, Han J, Yang Q, Zhang Y, Chen Y, Li P et al (2011) Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia. Neuroscience 178:169–180. doi:10.1016/j.neuroscience.2011.01.007
20. Zhang C, Du F, Shi M, Ye R, Cheng H, Han J, Ma L, Cao R et al (2012) Ginsenoside Rd protects neurons against glutamate-induced excitotoxicity by inhibiting ca(2+) influx. Cell Mol Neurobiol 32(1):121–128. doi:10.1007/s10571-011-9742-x
21. Chamorro A, Hallenbeck J (2006) The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 37(2):291–293. doi:10.1161/01.STR.0000200561.69611.f8
22. Samson Y, Lapergue B, Hosseini H (2005) Inflammation and ischaemic stroke: current status and future perspectives. Rev Neurol (Paris) 161(12 Pt 1):1177–1182
23. Trendelenburg G (2008) Acute neurodegeneration and the inflammasome: central processor for danger signals and the inflammatory response? J Cereb Blood Flow Metab 28(5):867–881. doi:10.1038/sj.jcbfm.9600609
24. Iadecola C, Alexander M (2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14(1):89–94
25. Zhang YX, Wang L, Xiao EL, Li SJ, Chen JJ, Gao B, Min GN, Wang ZP et al (2013) Ginsenoside-Rd exhibits anti-inflammatory activities through elevation of antioxidant enzyme activities and inhibition of JNK and ERK activation in vivo. Int Immunopharmacol 17(4):1094–1100
26. Zhang Y, Zhou L, Zhang X, Bai J, Shi M, Zhao G (2012) Ginsenoside-Rd attenuates TRPM7 and ASIC1a but promotes ASIC2a expression in rats after focal cerebral ischemia. Neurological Sci Offic J Ital Neurol Soc Ital Soc Clin Neurophysiol 33(5):1125–1131. doi:10.1007/s10072-011-0916-6
27. Yenari MA, Giffard RG (2001) Ischemic vulnerability of primary murine microglial cultures. Neurosci Lett 298(1):5–8
28. Yenari MA, Kauppinen TM, Swanson RA (2010) Microglial activation in stroke: therapeutic targets. Neurotherapeutics 7(4):378–391. doi:10.1016/j.nurt.2010.07.005
29. Dixit V, Mak TW (2002) NF-kappaB signaling. Many roads lead to madrid. Cell 111(5):615–619
30. Chen J, Chen ZJ (2013) Regulation of NF-kappaB by ubiquitination. Curr Opin Immunol 25(1):4–12. doi:10.1016/j.coi.2012.12.005
31. Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3):344–362. doi:10.1016/j.cell.2008.01.020
32. Quinn TJ, Dawson J, Walters MR, Lees KR (2009) Reliability of the modified Rankin Scale: a systematic review. Stroke 40(10):3393–3395. doi:10.1161/STROKEAHA.109.557256
33. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, Matchar D, Sehra R et al (2012) Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 43(4):1163–1170. doi:10.1161/STROKEAHA.111.641423
34. Saver JL (2011) Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke 42(8):2356–2362. doi:10.1161/STROKEAHA.111.619122
35. Chen YF (2012) Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci (Elite Ed) 4:809–817
36. Kaste M (2012) Is the door open again for neuroprotection trials in stroke? Lancet Neurol 11(11):930–931. doi:10.1016/S1474-4422(12)70229-6
37. Kaste M (2012) Is there a future for neuroprotective agents in acute ischaemic stroke? Eur J Neurol Offic J Eur Fed Neurol Soc 19(6):797–798. doi:10.1111/j.1468-1331.2011.03633.x
38. Muir KW, Tyrrell P, Sattar N, Warburton E (2007) Inflammation and ischaemic stroke. Curr Opin Neurol 20(3):334–342. doi:10.1097/WCO.0b013e32813ba151
39. Wang L, Zhang Y, Wang Z, Li S, Min G, Wang L, Chen J, Cheng J et al (2012) Inhibitory effect of ginsenoside-Rd on carrageenan-induced inflammation in rats. Can J Physiol Pharmacol 90(2):229–236. doi:10.1139/y11-127
40. Yang XL, Guo TK, Wang YH, Huang YH, Liu X, Wang XX, Li W, Zhao X et al (2012) Ginsenoside Rd attenuates the inflammatory response via modulating p38 and JNK signaling pathways in rats with TNBS-induced relapsing colitis. Int Immunopharmacol 12(2):408–414. doi:10.1016/j.intimp.2011.12.014